ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Clinical, surgical, and molecular features of pediatric supratentorial ependymomas: a single-institution experience.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSupratentorial pediatric ependymomas (ST-EPNs) represent a rare and biologically heterogeneous subgroup of central nervous system tumors. The 2021 WHO molecular classification has redefined their diagnostic framework, emphasizing prognostic and therapeutic implications. This study analyzes clinical, surgical, and molecular features of pediatric ST-EPNs treated at a single-institution, with particular focus on outcomes and prognostic variables.
methodsWe retrospectively reviewed pediatric patients with histologically confirmed supratentorial ependymomas treated between 2007 and 2023. Tumors were reclassified according to the 2021 WHO molecular criteria. Clinical presentation, imaging characteristics, tumor location, molecular subtype, extent of resection, adjuvant therapies, recurrence patterns, and long-term outcomes were evaluated.
resultsTwelve patients were included (mean age 7.4 years). Two tumors were intraventricular and ten extraventricular. Molecular profiling identified ZFTA fusion-positivity in 11 cases and YAP1 fusion-positivity in one case. Gross total resection was achieved in 11 of 12 patients, whereas one patient underwent near-total resection because of vascular encasement of the middle cerebral artery, making complete resection unsafe. Intraventricular tumors presented earlier, required complex surgical management, and were associated with higher treatment burden. Extraventricular tumors commonly presented with seizures and cystic imaging features, with favorable postoperative recovery. Recurrence occurred in 3 patients, successfully managed with repeat surgery and adjuvant therapy. At a mean follow-up of 8 years, all patients were alive with good neurological outcomes. Secondary neoplasms were observed in isolated cases following multimodal treatment.
conclusionThis single-institution molecularly reclassified series highlights clinically relevant differences between intraventricular and extraventricular pediatric supratentorial ependymomas in presentation, surgical complexity, and treatment burden. Our findings support maximal safe resection as the central therapeutic strategy while emphasizing the value of integrated molecular diagnostics and prolonged surveillance, particularly in light of late recurrence and secondary neoplastic events.
Indexed as
Identifiers
42240695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.